卡非佐米方案在虚弱复发或难治性多发性骨髓瘤患者中的疗效与安全性
本文为ASPIRE、ENDEAVOR和ARROW三项3期研究的事后分析,评估卡非佐米联合方案在虚弱复发或难治性多发性骨髓瘤患者中的疗效与安全性。虚弱患者中,KRd27、Kd56和每周Kd70方案较对照显示一致的疗效与安全性,治疗不应受虚弱状态限制。
要点
- 虚弱患者中KRd27较Rd的PFS为24.1 vs 15.9个月,HR 0.78(95%CI 0.54-1.12)。
- 虚弱患者中Kd56较Vd的PFS为18.7 vs 6.6个月,HR 0.50(95%CI 0.36-0.68)。
- 三项研究中虚弱患者≥3级治疗中出现不良事件发生率与主研究一致。
核心结论
- 在虚弱复发或难治性多发性骨髓瘤患者中,含卡非佐米方案较对照显示一致的疗效与安全性,治疗不应受虚弱状态限制。
研究设计与样本
- ASPRE、ENDEAVOR和ARROW三项3期研究的事后分析,虚弱患者样本量分别为196、330和141例。
- 虚弱分类采用纳入年龄、Charlson合并症指数和体能状态的算法,分为fit、intermediate和frail。
主要发现
- ASPIRE中虚弱患者KRd27 vs Rd的中位PFS为24.1 vs 15.9个月(HR 0.78;95%CI 0.54-1.12),中位OS为36.4 vs 26.2个月(HR 0.79;95%CI 0.57-1.08)。
- ENDEAVOR中虚弱患者Kd56 vs Vd的中位PFS为18.7 vs 6.6个月(HR 0.50;95%CI 0.36-0.68),中位OS为33.6 vs 21.8个月(HR 0.75;95%CI 0.56-1.00)。
- ARROW中虚弱患者每周Kd70 vs 每周两次Kd27的中位PFS为10.3 vs 6.6个月(HR 0.76;95%CI 0.49-1.16)。
- 三项研究中虚弱患者≥3级治疗中出现不良事件发生率与主研究一致。
关键数值与推荐
- ASPIRE方案:卡非佐米27 mg/m2联合来那度胺和地塞米松(KRd27)对比来那度胺和地塞米松(Rd)。
- ENDEAVOR方案:卡非佐米56 mg/m2联合地塞米松(Kd56)对比硼替佐米和地塞米松(Vd)。
- ARROW方案:每周一次卡非佐米70 mg/m2联合地塞米松(Kd70)对比每周两次卡非佐米27 mg/m2联合地塞米松(Kd27)。
临床怎么用
- 对于虚弱复发或难治性多发性骨髓瘤患者,KRd27、Kd56和每周Kd70方案可提供一致的疗效与安全性,不应仅因虚弱状态限制使用。
局限性
- 本文为事后分析,虚弱分类基于研究纳入的年龄、Charlson合并症指数和体能状态算法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Frailty is most prevalent among elderly multiple myeloma (MM) patients, and frail patients have a higher risk of poor outcomes due to reduced performance status or comorbidities. This post hoc analysis assessed efficacy and safety of carfilzomib combinations in frail patients with relapsed and/or refractory MM from the phase 3 ASPIRE (carfilzomib [27 mg/m2]-lenalidomide-dexamethasone [KRd27] vs lenalidomide-dexamethasone [Rd]), ENDEAVOR (carfilzomib [56 mg/m2]-dexamethasone [Kd56] vs bortezomib-dexamethasone [Vd]), and ARROW (once-weekly carfilzomib [70 mg/m2]-dexamethasone [Kd70] vs carfilzomib [27 mg/m2]-dexamethasone [Kd27]) studies. A frailty algorithm incorporating age, Charlson comorbidity index, and performance status classified patients as fit, intermediate, or frail. Results are presented for frail patients (ASPIRE, n = 196; ENDEAVOR, n = 330; ARROW, n = 141). In ASPIRE, median progression-free survival (PFS) (hazard ratio; 95% confidence interval) was 24.1 (KRd27) vs 15.9 months (Rd) (0.78; 0.54-1.12); median overall survival (OS) was 36.4 vs 26.2 months (0.79; 0.57-1.08). In ENDEAVOR, median PFS was 18.7 (Kd56) vs 6.6 months (Vd) (0.50; 0.36-0.68); median OS was 33.6 vs 21.8 months (0.75; 0.56-1.00). In ARROW, median PFS was 10.3 (once-weekly Kd70) vs 6.6 months (twice-weekly Kd27) (0.76; 0.49-1.16). In all 3 studies, rates of grade ≥3 treatment-emergent adverse events were consistent with those observed in the primary studies. The ASPIRE, ENDEAVOR, and ARROW primary analyses demonstrated favorable benefit-risk profiles with carfilzomib-containing regimens compared with controls. Across clinically relevant subgroups, including those by frailty status, consistent efficacy and safety were observed with KRd27, Kd56, and weekly Kd70, and treatment with these regimens should not be restricted by frailty status.
引用
- Facon T, Niesvizky R, Mateos MV, et al. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Adv. 2020. PMID: 33166401. doi:10.1182/bloodadvances.2020001965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。